Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. J of Skin 2023, 7 (2), s114. https://doi.org/10.25251/skin.7.supp.114.